Our treatment strategy showed positive responses in refractory AML primary samples treated with FLT3-A192, CD99-A192, and Co-Assembled formulations, highlighting the potential of our antibody-based fusion proteins. The gene discussed is CD99; the disease is acute myeloid leukemia.